BenjaminMichaelSchwartzMD, MHCM, FACOG, FACS

Obstetrics & Gynecology • Brightwaters, NY

Gynecologic Oncology

SVP and Regional Physician Executive; Chairman, Department of Obstetrics & Gynecology

Join to view full profile

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schwartz's full profile

Already have an account?

Office
404 Potter Boulevard
Brightwaters, NY 11718
Phone+1 631-376-0055

Fax+1 631-376-0099

Education & Training

Cleveland Clinic FoundationFellowship, Gynecologic Oncology, 2002
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Obstetrics and Gynecology, 1995 - 1999
George Washington University School of Medicine and Health SciencesClass of 1995

Certifications & Licensure

NY State Medical License 1997 - 2025
OH State Medical License 1999 - 2004
PA State Medical License 2001 - 2004
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19
Active, not recruiting
Not Applicable
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Intraoperative Indocyanine Green Dye Use in Ovarian Torsion: A Feasibility Study.
Kaitlin Nicholson, Anze Urh, Kristen Demertzis, Anastasiya Holubyeva, Zoe LaPier
Journal of Minimally Invasive Gynecology. 2022-06-01
1 citations
The Risk of Readmission after Early Postpartum Discharge during the COVID-19 Pandemic.
Moti Gulersen, Gregg Husk, Erez Lenchner, Matthew J Blitz, Timothy J Rafael
American Journal of Perinatology. 2022-03-01
A Vulvar Venous Malformation in a 14-Year-Old Adolescent.
Ana Cisneros-Camacho, Luis A. Bracero, Benjamin Schwartz
The Journal of Adolescent Health. 2021-07-01

Press Mentions

A New Way to Strengthen the Doctor-Patient RelationshipMay 16th, 2019
HPV Vaccine Safe for Adult Women: StudyOctober 18th, 2017
As Zika Spreads in California, Leaders Call for More Money, EducationSeptember 17th, 2016
Join now to see all

Professional Memberships

Society of Laparoendoscopic Surgeons - SLS
Member
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member